Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute discusses the common questions and concerns regarding her presentation on commercially prescribed PD-1 inhibitors in non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Common Questions Regarding Data on Commercially Prescribed PD-1 Inhibitors
